Daclizumab
Based on 1 Customer Validation
Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 152923-56-3
- Molecular Weight:144.24 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
|
IL-2 |
Daclizumab (10 μg/mL) significantly inhibits late-phase CD40L expression on activated human CD4+T cells (both naive CD45RA+CD45RO- and memory CD45RA-CD45RO+ subsets) in PBMC cultures stimulated with anti-CD3/anti-CD28[2].
Daclizumab (10 μg/mL) abolishes the restoration of CD40L expression by recombinant IL-2 (rIL-2), confirming that CD28-dependent CD40L expression is mediated via IL-2R signaling[2].
Daclizumab (10 μg/mL) inhibits CD40L expression on Th1-polarized (cultured with rIL-12, rIL-2, anti-IL-4) and Th2-polarized (cultured with rIL-4, low-dose rIL-2) human CD4+ T cells after restimulation[2].
Daclizumab (10 μg/mL, 48 h) inhibits CD40L expression on cells that divided once and reduces expression on non-dividing cells[2].
Daclizumab (10 μg/mL, 48-72 h) markedly inhibits rIL-12-enhanced CD40L expression in PBMC cultures[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MET-1 human T-cell leukemia cells (1.5 × 107 in intraperitoneal injection) were implanted into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice[3]
-
Dosage:100 μg/mouse
-
Administration:i.v., once weekly for 4 weeks on days 0, 7, 14, 21
-
Result:Achieved significant reduction in serum human β2-microglobulin.
Prolonged survival of leukemia-bearing mice.
Did not cause abnormal pathologic changes in major organs (liver, kidney, intestine, lung, bone marrow, heart) during observation.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized IL-2R alpha/CD25 Protein, Human, HEK293, N-His, HY-P7215) can bind Daclizumab. The EC50 for this effect is 16.81 ng/mL. -
Flow Cytometry analysis of Romas cells labelling IL-2Ra/CD25 (red) with Daclizumab (anti-IL-2Ra/CD25) (HY-P108738). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 152923-56-3
-
Appearance Liquid
-
Molecular Weight 144.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Daclizumab]
-
Synonyms
Ro 24-7375
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Cohan SL, et al. Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines. 2019 Mar 11;7(1):18. [Content Brief]
[2]. Snyder JT, et al. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood. 2007 Jun 15;109(12):5399-406. [Content Brief]
[3]. Zhang Z, et al. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood. 2006 Aug 1;108(3):1007-12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz